7 Dec 2021 07:00
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Belluscura PLC
("Belluscura" or the "Company" or "Group")
Exercise of Warrants and Total Voting Rights
Director / PDMR Shareholding
LONDON, U.K. AND PLANO, TX, U.S. (7 December 2021). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that it has received notification from staff warrant holders to exercise warrants over 348,506 shares in the share capital of Belluscura ("the Warrant Shares") at exercise prices of 13 pence (308,506 shares) and 15 pence (40,000 shares). The consideration for the exercise of the Warrant Shares amounts, in aggregate, to a cash value of £46,555.72.
The Company was notified that on 6 December 2021 Chief Executive Officer Robert Rauker exercised 179,537 Warrant Shares at an average price of 13.45 pence per share. Mr Rauker now holds 955,684 shares and his total interest in the Company has increased to 0.84% of the Company's enlarged issued share capital.
The Company was also notified that on 6 December 2021 Chief Financial Officer Tony Dyer exercised 141,404 Warrant Shares at a price of 13.00 pence per share. Mr Dyer now holds 778,345 shares and his total interest in the Company has increased to 0.68% of the Company's enlarged issued share capital.
The Warrant Shares were allotted on 6 December 2021. Application has been made for the Warrant Shares to be admitted to trading on AIM ("Admission"), and Admission is expected to be on or around 10 December 2021. These shares will rank pari passu with the ordinary shares of the Company in issue.
Total voting rights
The Company's total issued capital, after the issue of the Warrant Shares, will be 113,835,444 ordinary shares. As the Company does not hold any shares in Treasury, this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company following Admission.
For further information please contact:
Belluscura plc | www.belluscura.com |
Robert Rauker, Chief Executive Officer | via Walbrook PR |
Anthony Dyer, Chief Financial Officer |
|
|
|
SPARK Advisory Partners Limited (NOMAD) | Tel: +44 (0)20 3368 3550 |
Neil Baldwin |
|
|
|
Dowgate Capital Limited (Broker) | Tel: +44 (0)20 3903 7715 |
James Serjeant / Nicholas Chambers |
|
|
|
Walbrook PR Ltd (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com |
Paul McManus / Sam Allen | Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 |
About Belluscura plc (www.belluscura.com)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.
Belluscura is listed on the AIM market of the London Stock Exchange (AIM: BELL).
Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.
1
| Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Anthony Dyer | |
2 | Reason for notification |
| |
a) | Position / status | Chief Financial Officer | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| |
a) | Name | Belluscura plc | |
b) | LEI | 213800BRJQZE56XBPW94 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
| |
a) | Description of the financial instrument, type of instrumentIdentification code | Ordinary shares of £0.01 each in Belluscura plcISIN : GB00BD3B8Z11 | |
b) | Nature of the transaction | Exercise of Warrants | |
c)
| Price(s) and volumes(s)
| Price
£0.13 | Volume
141,404 |
d) | Aggregated information | n/a | |
e) | Date of the transaction | 6 December 2021 | |
f) | Place of the transaction | Outside a trading venue | |
Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.
1
| Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Robert Rauker | |
2 | Reason for notification |
| |
a) | Position / status | Chief Executive Officer | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| |
a) | Name | Belluscura plc | |
b) | LEI | 213800BRJQZE56XBPW94 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
| |
a) | Description of the financial instrument, type of instrumentIdentification code | Ordinary shares of £0.01 each in Belluscura plcISIN : GB00BD3B8Z11 | |
b) | Nature of the transaction | Exercise of Warrants | |
c)
| Price(s) and volumes(s)
| Price £0.13 £0.15 | Volume 40,000 139,537 |
d) | Aggregated information | n/a | |
e) | Date of the transaction | 6 December 2021 | |
f) | Place of the transaction | Outside a trading venue | |
Belluscura (BELL)